626207-32-7

Basic information

• Product Name: N-NONYLZINC BROMIDE
• Synonyms: N-NONYLZINC BROMIDE;n-Nonylzinc broMide, 0.5M in THF, packaged under Argon in resealable CheMSeal^t bottles;n-Nonylzinc bromide, Packaged under Argon in resealable ChemSeal? bottles;n-Nonylzinc bromide 0.5M in Tetrahydrofuran
• CAS NO: 626207-32-7
• Molecular Formula: C9H19BrZn
• Molecular Weight: 0
• Mol File: 626207-32-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Sensitive: Air Sensitive
• CAS DataBase Reference: N-NONYLZINC BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-NONYLZINC BROMIDE(626207-32-7)
• EPA Substance Registry System: N-NONYLZINC BROMIDE(626207-32-7)

Safety Data

• HazardClass: 4.3
• Hazardous Substances Data: 626207-32-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H19.BrH.Zn/c1-3-5-7-9-8-6-4-2;;/h1,3-9H2,2H3;1H;/q;;+1/p-1/rC9H19BrZn/c1-2-3-4-5-6-7-8-9-11-10/h2-9H2,1H3

Upstream product

• 693-58-3 1-Bromononane 
• 7440-66-6 zinc 

Downstream Products

• 29138-83-8 1-nonylindane 

Relevant articles and documents

Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease

We report on the synthesis and biological evaluation of a series of α-1-C-alkylated 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives as pharmacological chaperones for Gaucher disease. The parent compound, DAB, did not show inhibition of human β-glucocerebrosidase but showed moderate intestinal α-glucosidase inhibition; in contrast, extension of α-1-C-alkyl chain length gave a series of highly potent and selective inhibitors of the β-glucocerebrosidase. Our design of α-1-C-tridecyl-DAB (5j) produced a potent inhibitor of the β-glucocerebrosidase, with IC50 value of 0.77 μM. A molecular docking study revealed that the α-1-C-tridecyl group has a favorable interaction with the hydrophobic pocket and the sugar analogue part (DAB) interacted with essential hydrogen bonds formed to Asp127, Glu235 and Glu340. Furthermore, α-1-C-tridecyl-DAB (5j) displayed enhancement of activity at an effective concentration 10-times lower than isofagomine. α-1-C-Tridecyl-DAB therefore provides the first example of a pyrrolidine iminosugar as a new class of promising pharmacological chaperones with the potential for treatment of Gaucher disease. 2016 The Royal Society of Chemistry.

α-1-C-Butyl-1,4-Dideoxy-1,4-Imino-L-Arabinitol as a second-Generation iminosugar-based oral α-Glucosidase inhibitor for improving postprandial hyperglycemia

We report on the synthesis and the biological evaluation of a series of α-1-C-alkylated 1,4-dideoxy-1,4-imino-l-arabinitol (LAB) derivatives. The asymmetric synthesis of the derivatives was achieved by asymmetric allylic alkylation, ring-closing metathesis, and Negishi cross-coupling as key reactions. α-1-C-Butyl-LAB is a potent inhibitor of intestinal maltase, isomaltase, and sucrase, with IC50 values of 0.13, 4.7, and 0.032 μM, respectively. Matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis revealed that this compound differs from miglitol in that it does not influence oligosaccharide processing and the maturation of glycoproteins. A molecular docking study of maltase-glucoamylase suggested that the interaction modes and the orientations of α-1-C-butyl-LAB and miglitol are clearly different. Furthermore, α-1-C-butyl-LAB strongly suppressed postprandial hyperglycemia at an early phase, similar to miglitol in vivo. It is noteworthy that the effective dose was about 10-fold lower than that for miglitol. α-1-C-Butyl-LAB therefore represents a new class of promising compounds that can improve postprandial hyperglycemia.